iotrolan has been researched along with Dermatitis Medicamentosa in 1 studies
iotrolan: nonionic, isotonic contrast medium designed for intrathecal use; RN given refers to cpd without isomeric designation; DL-3-117 refers to stereoisomer; structure given in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| "A 46-year-old male developed wide-spread erythema and edema after intravenous injection of a CT contrast medium (iotrolan)." | 3.68 | Late phase allergic reaction to a CT contrast medium (iotrolan). ( Kanzaki, T; Sakagami, H, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kanzaki, T | 1 |
| Sakagami, H | 1 |
1 other study available for iotrolan and Dermatitis Medicamentosa
| Article | Year |
|---|---|
Late phase allergic reaction to a CT contrast medium (iotrolan).
Topics: Contrast Media; Drug Eruptions; Erythema; Humans; Hypersensitivity, Delayed; Injections, Intravenous | 1991 |